Axogen Inc vs Burlington Stores Inc — how do they compare? Axogen Inc trades at $49.81 (market cap $2.61B), while Burlington Stores Inc trades at $354.77 (market cap $22.59B). The key difference: Burlington Stores Inc is far larger — about 8.7× Axogen Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Burlington Stores Inc nearer its low. Which is the better fit depends on your goals.
| AXGN | BURL | |
|---|---|---|
Market Cap | $2.61B | $22.59B |
Sector | Technology | Consumer Cyclical |
52-Week High | $48.48 | $372.19 |
52-Week Low | $14.16 | $242.43 |
Enterprise Value | $2.52B | $27.71B |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.
The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.
Burlington Stores (BURL) trades at $351.88, down 5.28% today but maintains strong technical support near $352. The company demonstrates robust fundamentals with revenue growth from $10.63B to $11.9B projected for 2026, net income margin expansion to 5.23%, and consistent earnings beats. Recent news highlights successful smaller-store strategy execution and multiple analyst upgrades. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $352 and resistance at $365.
BURL presents a compelling growth story with 94% analyst buy ratings and a $367 consensus target offering 4.3% upside. The retailer's margin expansion and store productivity improvements drive optimism, though competitive pressures and consumer spending sensitivity pose risks. Institutional ownership trends show mixed activity with recent insider selling offset by fund position increases.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →